Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent & Trademark Office has issued a new patent to Helix BioPharma for the non-small cell lung cancer (NSCLC)-specific antibody component of its L-DOS47 drug candidate.
Subscribe to our email newsletter
L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic NSCLC.
According to Helix, L-DOS47 will stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival.
Helix BioPharma chairman and CEO said this patent protects the antibody entity that is used to construct L-DOS47, and in turn adds significant strength to L-DOS47’s patent protection.